Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients - Archive ouverte HAL Access content directly
Journal Articles British Journal of Clinical Pharmacology Year : 2017

Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients

(1) , , (2) , (2) , (2) , (2) , (2) , (3) , , (2) , (2)
1
2
3
Soujanya Ratna Edupuganti
  • Function : Author
Julien Mélet
  • Function : Author

Abstract

Rituximab is a monoclonal antibody directed against CD20, which is approved in rheumatoid arthritis (RA). This study aimed at assessing the influence of CD19+ cell counts as target-antigen amount, and of immunoglobulin G (IgG) serum concentrations on rituximab pharmacokinetics in RA patients.

Dates and versions

hal-02425330 , version 1 (30-12-2019)

Identifiers

Cite

Bertrand Lioger, Soujanya Ratna Edupuganti, Denis Mulleman, Christophe Passot, Celine Desvignes, et al.. Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients. British Journal of Clinical Pharmacology, 2017, 83 (8), pp.1773-1781. ⟨10.1111/bcp.13270⟩. ⟨hal-02425330⟩
27 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More